Pfizer’s Phase 2b obesity data put monthly GLP-1 dosing back in investor focus
Find out how Pfizer’s berobenatide Phase 2b data could reshape monthly GLP-1 obesity treatment and late-stage trial strategy.
Pharma & Biotech
Pharma & Biotech
Johnson & Johnson’s CAPLYTA update raises the bar for long-term schizophrenia stability
Schizophrenia drugs face a durability test. CAPLYTA’s FDA update gives Johnson & Johnson a stronger long-term stability story.
Pharma & Biotech
Why Humacyte, Inc.’s vascular tissue platform is gaining attention in high-risk dialysis populations
Why Humacyte, Inc.’s ATEV is gaining traction in dialysis care. Explore clinical data, risks, and what comes next in vascular access innovation.
Pharma & Biotech
Why the Veradermics hair loss trial is bigger than another aesthetics readout
Hair loss drugs are old, demand is huge, and Veradermics now faces the data test that could reset oral minoxidil’s commercial future.
Pharma & Biotech
Why Star Therapeutics’ FDA win for VGA039 could reshape the von Willebrand disease treatment race.
Star Therapeutics won dual FDA designations for VGA039 in von Willebrand disease. Read what it could change, and what still needs proving.
Pharma & Biotech
Could Ampligen become a late-stage pancreatic cancer breakthrough after AIM ImmunoTech’s latest clinical push?
Can Ampligen’s Phase 3 push reshape pancreatic cancer treatment? Read how AIM ImmunoTech’s latest clinical progress could change the oncology outlook.
Pharma & Biotech
Why Inhibikase Therapeutics’ pivotal PAH study may become a major 2026 biotech catalyst
Inhibikase Therapeutics begins pivotal Phase 3 testing of IKT-001 in PAH. Discover what this means for approval odds, clinicians, and investors.
Pharma & Biotech
Extended-interval nAMD therapy gets a new contender as Innovent Biologics posts Phase 3 STAR data
Innovent Biologics’ efdamrofusp alfa cleared a key Phase 3 nAMD hurdle in China. Read what the STAR data could change for retinal treatment.
Pharma & Biotech
Can Prestige Biopharma turn HD204 Phase 3 data into a credible Avastin biosimilar launch?
Prestige Biopharma reported positive HD204 Phase 3 data in NSCLC. Read what the bevacizumab biosimilar result could change next.
Pharma & Biotech
Theriva Biologics leverages FDA and EMA feedback to optimize VCN-01 pivotal trial
Theriva Biologics advances VCN-01 into phase 3 for metastatic pancreatic cancer with FDA and EMA guidance. Explore trial design, dosing strategy, and risks.